Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies Article

Industry Collaboration International Collaboration

author list

  • Bachert, Claus; Peters, Anju T.; Heffler, Enrico; Han, Joseph K.; Olze, Heidi; Pfaar, Oliver; Chuang, Chien-Chia; Rout, Raj; Attre, Richa; Goga, Ledia; Jacob-Nara, Juby A.; Rowe, Paul J.; Deniz, Yamo; Chen, Zhen; Kamat, Siddhesh; Siddiqui, Shahid

publication date

  • February 1, 2022


published in



  • CRSwNP
  • ENT (rhinitis, sinusitis, nasal polyps)
  • clinical immunology
  • quality of life
  • responder analysis
  • rhinitis

start page

  • 244

end page

  • 249


  • 52


  • 2